Pathogen-Reduced Red Blood Cells Are Safe in Cardiac Surgery: ReCePI Phase 3 Shows Noninferior AKI Rates

Pathogen-Reduced Red Blood Cells Are Safe in Cardiac Surgery: ReCePI Phase 3 Shows Noninferior AKI Rates

The ReCePI randomized phase 3 trial found that amustaline/glutathione pathogen-reduced red blood cells produced similar rates of acute kidney injury compared with conventional transfusion after cardiac or thoracic-aorta surgery, with few treatment-emergent antibodies and no clinically significant hemolysis.
Evaluating Cost-Effectiveness of Accelerated Versus Standard Initiation of Renal Replacement Therapy in Severe Acute Kidney Injury

Evaluating Cost-Effectiveness of Accelerated Versus Standard Initiation of Renal Replacement Therapy in Severe Acute Kidney Injury

This analysis reveals that standard initiation of kidney replacement therapy (KRT) in critically ill patients with severe acute kidney injury (AKI) offers greater quality-adjusted life years (QALYs) at an acceptable increased cost, suggesting cost-effectiveness in Canadian healthcare settings.